{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:43:44Z","timestamp":1760316224441,"version":"build-2065373602"},"reference-count":43,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2012,1,3]],"date-time":"2012-01-03T00:00:00Z","timestamp":1325548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2012,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Bortezomib has demonstrated efficacy in patients with relapsed B\u2010cell non\u2010Hodgkin lymphoma (NHL) both alone and in combination with other agents; however, limited data exist regarding its toxicity in combination with common frontline therapies for indolent NHL. A phase 1 study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone (R\u2010CHOP) was conducted in patients with untreated follicular lymphoma (FL) and other indolent NHLs.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Nineteen patients, including 10 patients with FL, were enrolled. The median patient age was 59 years (range, 29\u201071 years). Seven patients had a FL International Prognostic Index score \u22653. R\u2010CHOP with the vincristine dose capped at 1.5 mg was administered on a 21\u2010day cycle for 6 to 8 cycles, and 1 of 3 dose levels of bortezomib (1.0 mg\/m<jats:sup>2<\/jats:sup> [n = 1], 1.3 mg\/m<jats:sup>2<\/jats:sup> [n = 6], or 1.6 mg\/m<jats:sup>2<\/jats:sup> [n = 12]) was administered on days 1 and 8 of each cycle using a Bayesian algorithm for dose escalation.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>The maximum tolerated dose (MTD) of bortezomib with modified R\u2010CHOP was reached at 1.6 mg\/m<jats:sup>2<\/jats:sup>. Dose\u2010limiting toxicity was observed in 5 patients (1 patient at a bortezomib dose of 1.0 mg\/m<jats:sup>2<\/jats:sup>, 1 patient at a bortezomib dose of 1.3 mg\/m<jats:sup>2<\/jats:sup>, and 3 patients at a bortezomib dose of 1.6 mg\/m<jats:sup>2<\/jats:sup>). Neuropathy occurred in 16 patients (84%), including 2 patients (11%) who experienced grade 3 sensory neuropathy. Grade 4 hematologic toxicity occurred in 4 patients. Of 19 evaluable patients, 100% responded, and the complete response rate was 68%. At a median follow\u2010up of 32 months, the 3\u2010year progression\u2010free survival rate was 89.5%.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Bortezomib combined with modified R\u2010CHOP produced high response rates without substantial increases in toxicity. A phase 2 study of R\u2010CHOP and bortezomib given at this established MTD is currently ongoing. Cancer 2012;3538\u20133548. \u00a9 2012 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.26660","type":"journal-article","created":{"date-parts":[[2012,1,4]],"date-time":"2012-01-04T20:36:19Z","timestamp":1325709379000},"page":"3538-3548","source":"Crossref","is-referenced-by-count":17,"title":["A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low\u2010grade B\u2010cell lymphomas"],"prefix":"10.1002","volume":"118","author":[{"given":"Rajni","family":"Sinha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Hanna Jean","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nassoma","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pareen J.","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Bumpers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Hutchison\u2010Rzepka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mourad","family":"Tighiouart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard T.","family":"Heffner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Jo","family":"Lechowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,3]]},"reference":[{"issue":"5","key":"e_1_2_7_2_2","first-page":"88","article-title":"CHOP plus rituximab chemoimmunotherapy of indolent B\u2010cell lymphoma","volume":"26","author":"Czuczman MS","year":"1999","journal-title":"Semin Oncol."},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500217312"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_7_6_2","first-page":"106","article-title":"Determining the benefits of chemotherapy for achieving complete response in patients with untreated advanced stage follicular lymphoma: a systematic review and meta\u2010analysis [abstract]","author":"Orina JN","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1495"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.020"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3696"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008395214584"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.7819"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2184"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90508-N"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2005.n.046"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.7980"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25509"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24518"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.1142"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2332"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2003.13603.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.76a.08070"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9"},{"volume-title":"Bayesian Methods for Cancer Phase I Clinical Trials","year":"2004","author":"Babb JS","key":"e_1_2_7_28_2"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2106"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"e_1_2_7_31_2","first-page":"116","article-title":"Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas\u2014final results of the randomized phase III study NHL 2\u20102003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany)","author":"Rummel MJ","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-314708"},{"volume-title":"Bendamustine hydrochloride and rituximab with or without bortezomib followed by rituximab with or without lenalidomide in treating patients with high\u2010risk stage II, stage III, or stage IV follicular lymphoma","year":"2010","author":"National Cancer Institute","key":"e_1_2_7_33_2"},{"key":"e_1_2_7_34_2","first-page":"106","article-title":"Phase I\/II trial of bortezomib + CHOP\u2010rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): phase I results","author":"Leonard JP","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08315.x"},{"issue":"18","key":"e_1_2_7_36_2","article-title":"A feasibility study of VcR\u2010CVAD with maintenance rituximab for untreated mantle cell lymphoma","volume":"25","author":"Kahl BS","year":"2007","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.1561"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.4786"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008416911099"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.171"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2007.n.034"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.191"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.26660","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.26660","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:51:46Z","timestamp":1760280706000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.26660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,3]]},"references-count":43,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2012,7,15]]}},"alternative-id":["10.1002\/cncr.26660"],"URL":"https:\/\/doi.org\/10.1002\/cncr.26660","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2012,1,3]]}}}